Dana-Farber, BrainStorm partner for stem cell trial

04/10/2013 | Pharmaceutical Business Review Online

Dana-Farber Cancer Institute will provide production facilities for BrainStorm Cell Therapeutics' NurOwn stem cell product for use in an upcoming midstage trial. The study will begin this year at the Mayo Clinic, Massachusetts General Hospital and University of Massachusetts Hospital.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care